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ABSTRACT 
Neurofibromatosis type 1 (NF1) or von Recklinghausen disease is one of the most 
common genetic diseases, affecting 1/4,000 individuals. It is transmitted by 
autosomal dominant inheritance and the gene NF1, which is responsible for the 
disease, is located on the long arm of chromosome 17. NF1 is characterized by varied 
expressions of the disease, even within the same family. 
We present the case of a 22-year-old patient with NF1 admitted in the Department of 
Neurosurgery for a two months history of diffuse intercostal nevralgias that did not 
respond to treatment and discuss the histopathological and immunohistochemical 
features of her cutaneous and spinal neurofibromas. 
Our case adds new data to the knowledge of the diverse biological behaviour of NF1, 
highlighting the fact that this condition is a complex disease even in the same 
individual. We report here a highly variability among neurofibromas in the same 
patient from a histopathological point of view. Our data are also important as they 
demonstrate the fact that the management of a patient with NF1, due to the various 
and complex manifestations of the disease, requires a multidisciplinary approach, 
including neurologist, neurosurgeon, ophthalmologist, plastic surgeon, derma-
tologist, radiologist and pathologist.   
 
 
INTRODUCTION 
Neurofibromatosis type I (NF1) is a complex neuro-cutaneous disease 
with dominant autosomal transmission, whose NFI gene is located on 
Chromosome 17. The definitive diagnosis needs the existence in the 
same individual of two or more criteria from the following seven main 
elements: a). six or more café-au-lait spots, larger than 5 mm in puberty 
and larger than 15 mm after puberty, disseminated on the whole body; 
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b). axillary and inguinal freckling (Crowe sign); c). two 
or more cutaneous or spinal nerve neurofibromas of 
any type or at least 1 plexiform neurofibroma; d). 
optic nerve glioma; e). two or more Lisch nodules (iris 
hamartomas); f). characteristic skeletal dysplasia; g). 
at least one first-degree relative affected by NF1 
(parent, sibling, child) (1). 
However, NF1 is characterized by varied 
expressions of the disease, even within the same 
family. 
We present the case of a 22-year-old patient with 
NF1 fulfilling five main criteria of the disease and 
discuss the histopathological features of her 
cutaneous and spinal neurofibromas highlighting 
the fact that NF1 is a complex disease even in the 
same individual.  
 
CASE PRESENTATION 
A 22-year-old female patient was referred to 
Neurosurgery Department, „Prof. Dr. N. Oblu” 
Emergency Clinical Hospital Iaşi, with a two months 
history of diffuse intercostal nevralgias that did not 
respond to treatment. 
The patient had a positive family history for von 
Recklinghausen’s disease. She had an uncle (44 
years-old), her father's brother, with NF1, who was 
diagnosed five months ago with plexiform 
neurofibromas of the spinal nerves (from D12 nerve 
roots to the sacral roots), the terminal segments 
showing the appearance of pelvic "masses".  
Our patient's past medical history revealed a 
diagnosis of NF1 that was established when she was 
8 years old as she has had already café-au-lait spots, 
disseminated on her limbs and trunk, and cutaneous 
soft, painless tumours, one of them located in her 
left retroauricular area.  
The tumour was incompletely excised when the 
patient was 12 years old and the diagnosis of a 
cutaneous diffuse neurofibroma was 
histopathologically established, thus confirming the 
diagnosis of von Recklinghausen's (NF1) disease. 
As the tumour slowly increased in size, after 9 
years a head Magnetic Resonance Imaging (MRI) was 
performed, identifying the presence of a lesion that 
developed in the dermis and distorted the left 
temporo-occipital region (FIGURE 1). 
The tumour was completely excised and the 
specimen was sent to the Pathology Department 
where it was processed using the standard 
histological technique. The immunohistochemical 
stainings were performed using anti-S-100 protein 
antibody, anti-Vimentin antibody, and a two-step 
staining technique (EnVision+ Dual Link System-HRP, 
Dako). On histological examination, an intact 
epidermis covered a relatively ill-defined dermal 
tumoural proliferation of Schwann cells with 
hyperchromatic wavy nuclei, few aggregates of 
pseudomeissnerian corpuscles, associated with 
fibroblasts and normal appearing nerve bundles. 
Tumour mass infiltrated the hypoderm, entrapping 
adipocytes and distorting serous gland acini. 
Immunopositivity for Vimentin in randomly arranged 
fibroblasts and intense immunopositivity for S-100 
protein in randomly arranged Schwann cells, but 
also in the cells of pseudomeissnerian corpuscles, 
established the final diagnosis: cutaneous 
neurofibroma with pseudomeissnerian corpuscles 
(FIGURES 2, 3, and 4). 
 
 
 
FIGURE 1. MRI T2 SE scan revealed a cutaneous tumour in the 
left temporo-coccipital region. 
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FIGURE 2. Cutaneous neurofibroma: a). Tumoral proliferation of 
Schwann cells with hyperchromatic wavy nuclei, which were 
intimately associated with fibroblasts and fine collagen 
strands. In some areas, there were aggregates of 
pseudomeissnerian corpuscles (HE, x100); b). tactile-
like/pseudomeissnerian corpuscles in tumoral mass (HE, x200). 
c). Small scattered fascicles of nerve bundles entrapped into 
the tumour mass (HE, x100); d). tumour mass infiltrated the 
hypoderm, entrapping adipocytes and distorting serous gland 
(HE, 1200). 
  
 
Figure 3. Intense immunopositivity for S100 protein in 
randomly arranged Schwann cells, but also in all cells located 
in the pseudomeissnerian corpuscles (anti – S100 protein, x 
200). 
 
 
 
FIGURE 4. Immunopositivity for vimentin in randomly arranged 
fibroblasts (anti - Vimentin, x 100). 
 
One year later, on admission in our hospital due to 
diffuse intercostals nevralgias, the patient's physical 
examination revealed: axillary and inguinal freckling, 
six café-au-lait spots with diameters ranging from 
1,5cm to 6 cm, located on the trunk, six cutaneous 
tumours that were soft, pink, painless, ranging from 
a few millimeters to 2 centimeters, which were 
located on the dorsal trunk and right shoulder 
(FIGURE 5). 
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FIGURE 5. a). On the dorsal inferior trunk there were several 
"café-au-lait" spots, along with red, soft, depressible tumours. 
b). On the dorsal superior trunk there were three large (ranging 
from 2 cm to 6 cm in long diameter) "café-au-lait" spots; c). On 
her right shoulder area there was a cutaneous soft, pink- 
colored tumour, with a diameter of 1.5cm. 
 
 
 
 
 
FIGURE 6. The contrast enhanced CT exam showed an 
intraforaminal and para-vertebral tumour formation with 
widening of the vertebral left foramen at D10-D11, with left 
paravertebral extension, being in contact with the superior 
pole of the left kidney. The nodular aspect of the lesion, visible 
in the sagital plane, is associated with the inclusion of the left 
D10 and D11 spinal roots into the tumoural mass, as seen in 
the axial image. a). Axial section in a parenchymal window; b). 
Axial section in a bone window; c). sagital section. 
 
An abdominal CT scan was performed and revealed 
the existence of a left paravertebral solid tumour, 
which was developed intraforaminal and para-
vertebral around the dorsal level D11. The tumour 
extended upward at the D10 level and downward at 
the D12 level, encompassing left D10 and D11 spinal 
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roots. The tumoural formation was solid, oval, well 
defined, with dimensions of 35/16 / 65mm (FIGURE 6). 
The standard laboratory tests values were in the 
normal range. 
Surgical intervention was performed by external 
approach at D11-D12 lateral level, with microsurgical 
total ablation of the tumour. The surgical specimen 
was sent to the Pathology Department of the same 
hospital for histopathological analysis.  
The specimen was fixed in formalin, embedded in 
paraffin, cut at 5 μm and stained with hematoxylin-
eosin (HE). On representative sections, immune-
histochemical stainings were performed using anti-
S-100 protein antibody, anti-Vimentin antibody, and 
a two-step staining technique (EnVision+ Dual Link 
System-HRP, Dako). Histological sections stained 
with HE showed a non-encapsulated tumour, 
consisting of neoplastic wavy Schwann cells, 
entrapped ganglion cells as the tumour extended to 
associated ganglia, a myxoid stroma, and delicate 
collagen fibers (FIGURE 7). S100 protein immune-
staining highlighted neoplastic Schwann cell 
component and ganglia cells of the spinal root that 
were entrapped into the tumour (Figure 8). Vimentin 
immunostaining revealed numerous fibroblasts 
(FIGURE 9). The final pathological diagnosis was spinal 
neurofibroma with tumoural infiltration of the 
associated ganglia.  
The ophthalmologic examination revealed 
myopia in both eyes (best corrected visual acuity in 
right eye was 1 with -1 D and in the left eye was 1 with 
– 0,5 D). The ophthalmoscopic examination showed 
normal appearance of the ocular fundus in both 
eyes. Direct photomotor reflex was bilaterally 
present. Intraocular pressure was within normal 
range: right eye = 12 mmHg and left eye = 13 mmHg. 
Both eyes presented many small, bright brown, oval, 
and dome-shaped irian nodules (Lisch nodules) 
(FIGURE 10). 
 
 
 
  
FIGURE 7. Spinal neurofibroma: a). non-encapsulated tumour 
made up of neoplastic wavy Schwann cells, a myxoid stroma, 
and delicate collagen (H-E, x100); Numerous ganglia cells 
entrapped into the tumour mass (HE, x100). 
 
FIGURE 8. Immunopositivity for S100 protein in neoplastic 
Schwann cells and ganglia cells (anti – S100 protein, x 100). 
 
 
FIGURE 9. Immunopositivity for vimentin in randomly arranged 
fibroblasts (anti - Vimentin, x 100). 
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FIGURE 10. Numerous small Lisch nodules at both eyes [a). right 
eye; b). left eye]. 
 
DISCUSSION 
There are suppositions that Ebers Papyrus case #873 
can represent the first mention of a case of 
neurofibromatosis type 1 (NF1) (2). The important 
landmarks in the history of the disease are the Irish 
neurosurgeon Robert William Smith, who, in 1849, 
realized a systematic review of clinical cases (3), and 
the German pathologist Friedrich Daniel von 
Recklinghausen (1833-1910), who fully described this 
condition in 1882. Von Recklinghausen introduced 
the term “neurofibroma” into clinical practice to 
define the benign tumours that accompany this 
disease. He was the first who found that these 
tumours develop from the peripheral nerve sheath, 
consisting of a mixture of Schwann cells and 
fibroblasts (4). In recognition of his discovery, the 
disease received his name.  
However, there are different forms of 
neurofibromatosis that VM Riccardi, the director of 
the Baylor NF Program (1978-1990), attempted to 
classify the disease in 1982 (5). He considered that 
there were eight types, but later, in 1986, Carey et al. 
proposed a new classification into only five types, as 
follows: NF1 - classical, NF2 - acoustic, NF3 - 
segmental, NF4 - CALM - familial and NF5 - NF-
Noonan phenotype (6).  
NF1 represents 90% of all cases with NF, being 
characterized mainly by multiple café-au-lait spots 
and neurofibromas along peripheral nerves. 
Even though NF1 has been recognized as a 
clinical entity for more than a century, its 
etiopathogenesis was better understand only in 
1990 when the NF1 gene was identified on 
chromosome 17. NF1 gene is a tumour suppressor 
gene that encodes a protein named neurofibromin 
(7), which is a negative regulator of the ‘‘rat sarcoma 
viral oncogene homologue’’ (RAS) (8). 
Approximately 50% of the cases with NF1 disease 
represent new mutations and the expression of the 
disease is highly variable, both between and within 
families (9). 
The most important hypothesis regarding the 
neurofibromas was that these tumours can develop 
only after both NF1 alleles have been lost in the 
Schwann cell lineage. When Schwann cells begin to 
proliferate, they recruit some other cells from their 
environment (10). As such, neurofibromas are 
complex tumours, consisting in a mixture of cell 
types: Schwann cells, fibroblasts, perineurial cells, 
and mast cells (7, 10).  
It was also hypothesized that these different 
cellular phenotypes can represent divergent cellular 
differentiation pathways of multipotent precursor 
cells (11). 
It was considered that the development of 
neurofibromas include the presence of a clonal 
population of NF1-/- Schwann cells in a 
microenvironment harbouring other cell types with 
an NF1+/- genotype. It was also hypothesised that 
the multipotent NF1+/- cells are the major source of 
different cell types found in the neurofibromas (11). 
Neurofibromas developing in a NF1-affected 
individual can be classified according to their 
anatomical location into: cutaneous, subcutaneous, 
intraneural, and spinal nerve roots tumours (12). 
Cutaneous neurofibromas generally appear 
during preadolescence. They are soft, pink coloured 
tumours, sessile or dome-shaped, being most 
numerous on the trunk and limbs. The tumour 
diameter usually varies between a few millimetres 
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and approximately 2 centimetres (11). It is 
considered that these benign tumours developed 
from small nerve tributaries of the skin (13). 
Histologically, cutaneous neurofibromas are 
nonencapsulated, loosely textured dermal mixed 
tumours, consisting of Schwann cells, neurons, 
perineurial cells, fibroblasts, and mast cells, but also 
adipocytes, epithelial cells, and axonal processes 
(11). All of these cellular elements are embedded in 
an abundant collagenous extracellular matrix. 
Megahed (14) described ten histopathological 
variants of neurofibroma: classic, cellular, myxoid, 
hyalinized, epithelioid, plexiform, diffuse, 
pigmented, granular cell, pacinian. Subsequently, 
some other variants such as dendritic cell 
neurofibroma with pseudorosettes (15), lipomatous 
neurofibroma (16), and angioneurofibroma (17) have 
been reported. Pseudomeissnerian corpuscles can 
be seen in cutaneous neurofibromas, but not so 
frequently. 
Using traditional histological staining as well as 
immunohistochemical staining (anti-S100 protein 
antibody and anti-Vimentin antibody) can be the 
proofs that the neoplastic component is made of 
Schwann cell. Neurofilament protein immune-
reactivity (NFP) revealed the occurrence of residual 
axons within tumour nodules. Some authors 
highlighted the fact that, using factor XIIIa as an 
immunohistochemical marker, the pathologist can 
differentiate cutaneous neurofibromas from 
neurotized nevi and cutaneous schwannomas (18.) 
Aggregates of pseudo-meissnerian corpuscles are 
frequent in diffuse cutaneous neurofibromas (19). As 
these structures consist entirely of Schwann cells, 
they can be can be highlighted with anti-S100 protein 
antibody immunostaining (20). 
Our patient presented at least one cutaneous 
neurofibroma since he was 8 years-old, but the 
definitive diagnosis of NF1 was realized only after the 
surgical excision of the tumour (when patient was 12 
years-old). Histological and immunohistochemical 
examinations identified diffuse cutaneous 
neurofibroma with clusters of organoid structures 
resembling Meissner corpuscles (pseudo-
meissnerian structures), thus being in line with other 
researchers' findings. 
The incidence of spinal involvement in NF1 
patients varies among authors. Mautner et al. 
reported that spinal neurofibromas are found in up 
to 38% of NF1 patients but very few of them are 
symptomatic (21). 
In a study of patients with NF1 made by Thakkar 
et al., 6% of patients had intramedullary tumours, 
57% had intraforaminal tumours (dumbbell), and 
33% had extradural tumours (22). 
At the spinal level, patients with NF1 may have 
either one or more tumours that can develop in one 
or more spinal nerve roots. Usually, spinal tumours 
are diffuse or plexiform neurofibromas. Some 
authors found out that more frequently these spinal 
tumours are solitary neurofibromas (23), but others 
reported plexiform neurofibromas, which grow 
involving multiple nerve fascicles, branches and 
plexuses (24). Our patient had a solitary spinal 
neurofibroma, but her uncle had multiple plexiform 
spinal neurofibromas. Our article prove the fact that 
neurofibromas developing in a patient with NF1 can 
have different histological features, each of them 
displaying microscopical appearances more closely 
related to the histology of the region in which the 
tumour occurs, i.e., cutaneous neurofibroma 
exhibited pseudomeissnerian corpuscle, and spinal 
neurofibroma revealed Schwann cells arranged in 
bundles, reminding of spinal nerve histology. 
The age at onset of symptoms caused by spinal 
neurofibromas can vary from 11 to 49 years (mean 
32.8 years), but most cases present symptoms at 
adult ages (22 to 43 years) (25). 
Spinal neurofibromas cause neurological 
symptoms in only 2% of NF1 patients, provoking 
both sensory and motor deficits due to compression 
of the spinal cord or nerve root (22). In a recent 
article, Mauda-Havakuk et al. analyzed the 
radiological findings of a series of thirty-four patients 
with NF1 with spinal neurofibromas. They classified 
spinal involvement into four types according to the 
anatomic location of the tumours along the spine 
and to their type of involvement of the spinal canal 
and foramina: 1. foraminal tumour; 2. “kissing” 
tumours; 3. paraspinal tumour; 4. intradural tumour 
(26). These authors reported that most spinal 
neurofibromas developed in the lumbo-sacral area 
and fell into group 1 (foraminal). 
Our patient was diagnosed as having a spinal 
foraminal neurofibroma at the age of 22. As her left 
D10 and D11 spinal roots were entrapped into the 
tumour mass, the patient presented a two months 
history of diffuse intercostal nevralgias that did not 
respond to the treatment, thus imposing the surgical 
intervention. 
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Lisch nodules are hamartomas of the iris that are 
also characteristic for NF1. They have variable 
dimensions and dome-shaped configuration. Some 
researchers reported that patients affected by NF1 
and older than twenty could have an incidence of 
Lisch nodules of 100% (27). Lewis et al. found out that 
92% of subjects aged 6 years and older had Lisch 
nodules, but their presence was not correlated to 
number of café-au-lait spots, number of 
neurofibromas, or severity of disease (28). Our 
patient, being in her third decade of life, also 
presented Lisch nodules in both her eyes. 
Due to varied and complex manifestations of the 
disease, the management of a patient with NF1 
requires a multidisciplinary approach. Once the 
diagnosis is established, clinical monitoring is 
needed to identify possible complications. As a 
result, annual assessment is required to reduce 
morbidity and improve the quality of life. This 
assessment should include: a) dermatological 
examination to analyze the progression of the 
existing neurofibromas and to identify possible new 
lesions; b). head and spine MRI, chest and abdomen 
imaging to detect the majority of complications that 
could be associated with this disease; c). full 
ophthalmological examination for early detection of 
optic nerve lesions; d). neurological examination for 
early detection of paresthesia, radiculopathy, muscle 
fatigue or muscle atrophy; e). removal of skin 
tumours for cosmetic or therapeutic purposes; f). 
education and psychological support for NF1 patient. 
 
CONCLUSION 
The patient described in this article is a very typical 
case of NF1, having six ”café-au-lait” spots, six 
neurofibromas, axillary or inguinal freckling, Lisch 
nodules, and a first degree relative (her father's 
brother) with NF1.Our case presents a considerable 
interest because of a complete description of the 
natural evolution of NF1, highlighting the histological 
pictures of her cutaneous and spinal neurofibromas. 
Because the expression of the disease is highly 
variable, both between and within families, our study 
data are especially valuable as they also showed a 
highly variability among neurofibromas in the same 
patient from a histopathological point of view. These 
data are also important as they demonstrate the fact 
that the management of a patient with NF1, due to 
the various and complex manifestations of the 
disease, requires a multidisciplinary approach, 
including neurologist, neurosurgeon, ophthalmol-
ogist, plastic surgeon, dermatologist, radiologist and 
pathologist. 
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